Inflammasome Therapeutics
Newton, US · Delaware corporation
Inflammasome Therapeutics develops treatments for degenerative diseases including Alzheimer's disease, multiple sclerosis, macular degeneration, and Parkinson's disease. Its approach targets inflammasome activation as a mechanism to treat these conditions.
Founders & leadership
PA
Paul AshtonCo-founder
JA
Jayakrishna AmbatiCo-founder
Board
BA
Balamurali AmbatiBoard director
JL
Joon LeeBoard director
NF
Napoleone FerraraBoard director
MW
Mary WeberBoard director
Reported raises · per SEC filings
Form D private placements$19.4M disclosed across 3 rounds · 2023–2026
▶$13.2MraisedMay 2026 · 62 investors · BiotechnologyRule 506(b)
▶$13.2MraisedMay 2026 · 62 investors · Biotechnology
Rule 506(b)Officers, directors & promoters on the filing
- Balamurali K. AmbatiExecutive Officer, Director
- Jayakrishna AmbatiExecutive Officer, Director
- Chaniyilparampu N. RamchandDirector
- Babur B. LateefDirector
- Napoleone FerraraDirector
- Offering amount
- $13.2M
- Amount sold
- $13.2M
- First sale
- Feb 2026
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$2.5MraisedMar 2025 · 27 investors · Other Health CareRule 506(b)
▶$2.5MraisedMar 2025 · 27 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Balamurali AmbatiDirector
- Joon LeeDirector
- Napoleone FerraraDirector
- Paul AshtonExecutive Officer, Director
- Jayakrishna AmbatiDirector
- Mary WeberDirector
- Offering amount
- $10M
- Amount sold
- $2.5M
- First sale
- Dec 2024
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$3.8MraisedJan 2024 · 24 investors · Other Health CareRule 506(b)
▶$3.8MraisedJan 2024 · 24 investors · Other Health Care
Rule 506(b)Officers, directors & promoters on the filing
- Joon LeeDirector
- Paul AshtonExecutive Officer, Director
- Jayakrishna AmbatiDirector
- Balamurali AmbatiDirector
- Mary WeberDirector
- Napoleone FerraraDirector
- Offering amount
- $3.8M
- Amount sold
- $3.8M
- First sale
- Aug 2023
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 2
by search overlapBioworld13 shared keywordsBioWorld is a suite of daily news and data services covering therapeutics, medical technology, biopharma business transactions, and drug R&D, serving biopharmaceutical and medtech industry professionals. Owned by Clarivate, it publishes products including BioWorld, BioWorld Science, and BioWorld Asia with reporting from writers stationed globally.
UPMC12 shared keywordsUPMC operates a network of hospitals and health care facilities, offering medical services and specialties such as cancer care, cardiology, neurosciences, orthopaedics, and behavioral health. It provides patient tools for finding doctors, locating facilities by region, and accessing patient portals.
Companies competing with Inflammasome Therapeutics for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Inflammasome Therapeutics do?
- Inflammasome Therapeutics develops treatments for degenerative diseases including Alzheimer's disease, multiple sclerosis, macular degeneration, and Parkinson's disease. Its approach targets inflammasome activation as a mechanism to treat these conditions.
- Who founded Inflammasome Therapeutics?
- Inflammasome Therapeutics was founded by Paul Ashton, Jayakrishna Ambati.
- How much funding has Inflammasome Therapeutics raised?
- Inflammasome Therapeutics has disclosed $19.4M raised across 3 rounds.
- Where is Inflammasome Therapeutics headquartered?
- Inflammasome Therapeutics is headquartered in Newton, US.